RxSight CFO exchanges 258K options at $6.375

RxSight’s CFO exchanged a 258,770-share option for a new option at a lower $6.375 exercise price with a revised vesting schedule.

Rhea-AI Filing Summary

RxSight, Inc. (RXST) reported that Chief Financial Officer Mark Wilterding participated in an option exchange on September 5, 2026. An existing stock option for 258,770 shares with a $10.09 exercise price was returned to the issuer and replaced on a 1:1 basis with a new option for 258,770 shares at a $6.375 exercise price. The new option vests in equal monthly installments over 24 months starting February 28, 2027, contingent on continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Wilterding Mark

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Disposition	Stock Option (right to buy) F2, F1	258,770	--	--
Grant/Award	Stock Option (right to buy) F2, F3	258,770	--	--

Holdings After Transaction: Stock Option (right to buy) — 258,770 contracts (Direct)

Footnotes (3)

1. F1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of January 11, 2026 (the "Vesting Commencement Date"), and the remaining shares subject to the options shall vesting equally monthly on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month) over the following three years, such that all of the shares subject to the option shall be fully vested four years from the Vesting Commencement Date.
2. F2. On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $6.375 per share.
3. F3. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one twenty-fourth (1/24th) of the shares subject to the option will vest on February 28, 2027 and in equal monthly installments thereafter.

Key Figures

Options exchanged: 258,770 option shares Original exercise price: $10.09 per share New exercise price: $6.375 per share +4 more

7 metrics

Options exchanged 258,770 option shares Number of shares underlying both the disposed and newly granted options on September 5, 2026

Original exercise price $10.09 per share Exercise price of the returned stock option expiring January 11, 2036

New exercise price $6.375 per share Exercise price of the new option granted in the option exchange program

Original option expiration January 11, 2036 Expiration date of the disposed option for 258,770 shares

New option expiration September 4, 2033 Expiration date of the new option for 258,770 shares

Initial vesting date (old option) January 11, 2027 25% of the old option was scheduled to vest one year from the January 11, 2026 Vesting Commencement Date

Initial vesting date (new option) February 28, 2027 1/24th of the new option vests on this date, with monthly vesting thereafter

Key Terms

option exchange program, Vesting Commencement Date, Service Provider

3 terms

option exchange program financial

"in connection with the Issuer's option exchange program, the Issuer exchanged"

Vesting Commencement Date financial

"on the one-year anniversary of January 11, 2026 (the "Vesting Commencement Date")"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

Service Provider financial

"Subject to the Reporting Person continuing to be a Service Provider"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RxSight (RXST) report for its CFO?

RxSight reported that CFO Mark Wilterding returned a stock option for 258,770 shares with a $10.09 exercise price and received a new option for 258,770 shares at a $6.375 exercise price on September 5, 2026, under the company’s option exchange program.

How many RxSight (RXST) options were involved in the CFO’s option exchange?

The option exchange involved 258,770 option shares. An existing option for 258,770 shares was disposed of back to the issuer and a new option for the same 258,770 shares was granted on a 1:1 basis, keeping the overall option share count unchanged.

What are the exercise prices of the RxSight (RXST) options in this Form 4?

The returned option had an exercise price of $10.09 per share. The new option granted in the exchange has an exercise price of $6.375 per share, as part of RxSight’s option exchange program described for the September 5, 2026 transaction.

What is the vesting schedule for the new RxSight (RXST) option granted to the CFO?

For the new option, one twenty-fourth (1/24th) of the 258,770 shares will vest on February 28, 2027, with the remainder vesting in equal monthly installments thereafter, subject to Mark Wilterding continuing to be a Service Provider under RxSight’s 2021 Equity Incentive Plan.

Was the RxSight (RXST) CFO’s option exchange under a Rule 10b5-1 trading plan?

The filing indicates the Rule 10b5-1 checkbox is not affirmed, and there is no footnote stating that the transactions were made under a Rule 10b5-1 trading plan. The option exchange is described in the context of RxSight’s option exchange program.

Did the RxSight (RXST) CFO’s Form 4 show a change in total option share count?

The reported transactions show a 1:1 exchange: an existing option for 258,770 shares was disposed of and a new option for 258,770 shares was granted. This indicates no change in the number of option shares reported in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 08:56 PM EDT Accepted by SEC EDGAR 09/09/2026 - 08:55 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wilterding Mark

(Last) (First) (Middle)

100 COLUMBIA

(Street)

ALISO VIEJO CALIFORNIA 92656

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RxSight, Inc. [ RXST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$10.09	09/05/2026		D			258,770	(1)	01/11/2036	Common Stock	258,770	(2)	0	D
Stock Option (right to buy)	$6.375	09/05/2026		A		258,770		(3)	09/04/2033	Common Stock	258,770	(2)	258,770	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of January 11, 2026 (the "Vesting Commencement Date"), and the remaining shares subject to the options shall vesting equally monthly on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month) over the following three years, such that all of the shares subject to the option shall be fully vested four years from the Vesting Commencement Date.

2. On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $6.375 per share.

3. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one twenty-fourth (1/24th) of the shares subject to the option will vest on February 28, 2027 and in equal monthly installments thereafter.

	/s/ Jim Schindler, as Attorney-in-Fact	09/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)